Saperstein Alice M, Choi C Jean, Jahshan Carol, Lynch David A, Wall Melanie, Green Michael F, Medalia Alice
Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons 1051 Riverside Drive, New York, NY 10032, United States.
Mental Health Data Science, New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, United States.
Schizophr Res. 2021 May;231:61-66. doi: 10.1016/j.schres.2021.03.006. Epub 2021 Mar 23.
Collaborative data sharing between research groups provides an opportunity to explore the basis for the heterogeneity in cognitive training outcomes reported in the schizophrenia literature. The current analyses focused on the contribution of site and participant characteristics to these heterogeneous outcomes.
Data from two independent studies, from New York (NY) and Los Angeles (LA), were combined to yield a sample of 132 outpatient adults with schizophrenia/schizoaffective disorder. While similar treatment doses, cognitive exercises and outcome measures were used, sites differed in use of coaching, group discussion and compensation. Between-site differences in participant demographic and baseline clinical characteristics were tested. Regression examined predictors of change in cognition (MCCB) and functional capacity (UPSA) which could explain site differences in treatment effects.
Medium to large treatment effect size differences in MCCB and UPSA favored the NY site over LA. When the studies were combined, the effect of site was significant for both outcomes with a medium effect size difference. After controlling for background characteristics, the effect of site was reduced for both outcomes, but remained significant for cognition. Improvement in UPSA was associated with better baseline MCCB (p < 0.001), lower baseline UPSA (p < 0.001) and younger age (p = 0.019). The overall model with site, baseline scores, and participant background characteristics explained about 30% to 40% of the variance in outcomes.
Participant and treatment characteristics are both predictive of outcomes, but treatment characteristics may be more consequential to cognitive gain, while participant characteristics may be more consequential to change in functional capacity.
研究团队之间的协作数据共享为探究精神分裂症文献中报道的认知训练结果异质性的基础提供了契机。当前分析聚焦于研究地点和参与者特征对这些异质性结果的影响。
来自纽约(NY)和洛杉矶(LA)的两项独立研究的数据被合并,形成了一个包含132名患有精神分裂症/分裂情感性障碍的门诊成年患者的样本。虽然使用了相似的治疗剂量、认知训练和结果测量方法,但研究地点在指导、小组讨论和补偿措施的使用上存在差异。对参与者人口统计学和基线临床特征的地点间差异进行了检验。回归分析考察了认知(MCCB)和功能能力(UPSA)变化的预测因素,这些因素可以解释治疗效果的地点差异。
MCCB和UPSA中到较大的治疗效果大小差异表明纽约地点优于洛杉矶地点。当两项研究合并后,地点对两个结果的影响均显著,效果大小差异为中等。在控制背景特征后,两个结果的地点影响均有所降低,但对认知仍具有显著性。UPSA的改善与更好的基线MCCB(p < 0.001)、更低的基线UPSA(p < 0.001)和更年轻的年龄(p = 0.019)相关。包含地点、基线分数和参与者背景特征的总体模型解释了结果中约30%至40%的方差。
参与者和治疗特征均对结果具有预测性,但治疗特征可能对认知增益更为重要,而参与者特征可能对功能能力的变化更为重要。